Logo Image
News
Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Media
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsShortsTraining Academy
Conferences
Conference CoverageConference Listing
Publications
More
CME/CE
Continuing Education
Resources
Case-Based Digest Rx Road MapEventsAdvanced Practice Corner
Partners

Subscribe

  • News
  • Media
  • Conferences
  • Publications
  • CME/CE
  • Resources
  • Subscribe
  • Partners
  • Brain Cancer
  • Breast Cancer
    • Metastatic Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Liver Cancer
    • Gastric Cancers
  • Genitourinary Cancer
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Cervical Cancer
    • Ovarian Cancer
  • Head and Neck Cancers
  • Hematology
    • Leukemia
    • Graft-Vs-Host Disease
    • Myeloproliferative Neoplasms
    • Multiple Myeloma
    • Lymphoma
  • Lung Cancer
  • Pediatric Cancer
  • Sarcomas
  • Skin Cancer
    • Melanoma
Advertisement

Sherry Adkins, MSN, ANP-C

Advertisement

Articles by Sherry Adkins, MSN, ANP-C

Sherry Adkins Talks Primary Care Provider Communication Following CAR T-cell Therapy

Sherry Adkins Talks Primary Care Provider Communication Following CAR T-cell Therapy

BySherry Adkins, MSN, ANP-C
August 12th 2022

Sherry Adkins, MSN, ANP-C, discusses some key considerations in ensuring quality patient care after they have completed CAR T-cell therapy at a specialized center.

Advertisement

Latest Updated Articles

  • Sherry Adkins Talks Primary Care Provider Communication Following CAR T-cell Therapy
    Sherry Adkins Talks Primary Care Provider Communication Following CAR T-cell Therapy

    August 12th 2022



Advertisement
Advertisement

Trending on Oncology Nursing News

1

AI and Oncology Nursing: Detecting Misdiagnosis With Molecular Profiling

2

FDA Approves Gedatolisib for HR+/HER2- Advanced Breast Cancer: What Nurses Need to Know

3

FDA Grants Traditional Approval to Selpercatinib for RET-Fusion Solid Tumors

4

FDA Approves Gedatolisib for HR+/HER2- Metastatic Breast Cancer

5

Managing Oncology Care Amidst Rising Wildfire Smoke and Poor Air Quality

  • About Us
  • Editorial Board
  • Contact Us
  • CancerNetwork.com
  • CureToday.com
  • OncLive.com
  • TargetedOnc.com
  • Advertise
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us